The effects of montelukast sodium in conjunction with budesonide/formoterol on pulmonary function and serum markers (interleukin-6, tumor necrosis factor-α, eosinophils (EOS) count) in obstructive airway diseases (asthma and chronic obstructive pulmonary disease).
{"title":"The effects of montelukast sodium in conjunction with budesonide/formoterol on pulmonary function and serum markers (interleukin-6, tumor necrosis factor-α, eosinophils (EOS) count) in obstructive airway diseases (asthma and chronic obstructive pulmonary disease).","authors":"Zhen Wang, Wei Zhang, Weifang Xu","doi":"10.5114/ada.2024.144825","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The research objective was to evaluate the effectiveness and safety of using montelukast sodium alongside budesonide/formoterol in individuals with obstructive airway diseases.</p><p><strong>Material and methods: </strong>A prospective study was conducted on 100 obstructive airway disease patients who had received treatment of budesonide/formoterol inhalation powder (control group, <i>n</i> = 50) or montelukast sodium tablets supplemented to budesonide/formoterol inhalation powder (observation group, <i>n</i> = 50). Both groups underwent a 3-month treatment, and the assessment of effectiveness relied on symptom improvement, with a comparative analysis of outcomes for symptoms such as cough, sputum, wheezing, and dyspnoea. The evaluation involved measuring pulmonary function indicators like FEV1 and FEV1/FVC as well as comparing serum markers such as interleukin-6, tumor necrosis factor-α, eosinophils count, and fractional exhaled nitric oxide.</p><p><strong>Results: </strong>With a total effective rate of 94.00%, the observation group showed a significant improvement in comparison to the control group, which achieved 80% effectiveness (<i>p</i> < 0.05). Additionally, the observation group experienced a significantly faster alleviation of symptoms such as cough, sputum, wheezing, and dyspnoea than the control group (<i>p</i> < 0.05). Post-treatment, the observation group showed significantly better pulmonary function and lower inflammatory markers in comparison to the control group (<i>p</i> < 0.05). Notably, there was no significant variance in the occurrence of adverse reactions between groups.</p><p><strong>Conclusions: </strong>Montelukast sodium in conjunction with budesonide/formoterol presents a pronounced advantage in effectiveness and safety for treating obstructive airway diseases in individuals. It effectively alleviates symptoms, enhances pulmonary function, and diminishes inflammation, offering critical insights for clinical management.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 4","pages":"393-397"},"PeriodicalIF":1.4000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12458069/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy Dermatologii I Alergologii","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ada.2024.144825","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: The research objective was to evaluate the effectiveness and safety of using montelukast sodium alongside budesonide/formoterol in individuals with obstructive airway diseases.
Material and methods: A prospective study was conducted on 100 obstructive airway disease patients who had received treatment of budesonide/formoterol inhalation powder (control group, n = 50) or montelukast sodium tablets supplemented to budesonide/formoterol inhalation powder (observation group, n = 50). Both groups underwent a 3-month treatment, and the assessment of effectiveness relied on symptom improvement, with a comparative analysis of outcomes for symptoms such as cough, sputum, wheezing, and dyspnoea. The evaluation involved measuring pulmonary function indicators like FEV1 and FEV1/FVC as well as comparing serum markers such as interleukin-6, tumor necrosis factor-α, eosinophils count, and fractional exhaled nitric oxide.
Results: With a total effective rate of 94.00%, the observation group showed a significant improvement in comparison to the control group, which achieved 80% effectiveness (p < 0.05). Additionally, the observation group experienced a significantly faster alleviation of symptoms such as cough, sputum, wheezing, and dyspnoea than the control group (p < 0.05). Post-treatment, the observation group showed significantly better pulmonary function and lower inflammatory markers in comparison to the control group (p < 0.05). Notably, there was no significant variance in the occurrence of adverse reactions between groups.
Conclusions: Montelukast sodium in conjunction with budesonide/formoterol presents a pronounced advantage in effectiveness and safety for treating obstructive airway diseases in individuals. It effectively alleviates symptoms, enhances pulmonary function, and diminishes inflammation, offering critical insights for clinical management.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
